Trials / Completed
CompletedNCT03052205
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Idera Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMO-2125 | IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle. |
Timeline
- Start date
- 2017-06-09
- Primary completion
- 2019-07-24
- Completion
- 2019-10-04
- First posted
- 2017-02-14
- Last updated
- 2020-02-11
Locations
12 sites across 2 countries: United States, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03052205. Inclusion in this directory is not an endorsement.